-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, there have been frequent changes in executives in the pharmaceutical industry at home and abroad
.
In China, more than 100 senior executives left last year alone, involving a large number of domestic and foreign pharmaceutical companies such as Pfizer, AstraZeneca, Ascentage, WuXi Biologics, Sinopharm, Hengrui, and Lexin
.
It is worth noting that the time has now entered 2022, and in just a few days at the beginning of the new year, there have been new changes in the executives of many pharmaceutical companies
.
Gan & Lee Pharmaceuticals Appoints Dr.
Mike Hu as CEO and General Manager of Gan & Lee AmericaOn January 3, Gan & Lee Pharmaceuticals announced that it has appointed Dr.
Mike Hu as Gan & Lee America's CEO and General Manager to lead and be responsible for the global clinical development of Gan & Lee Pharmaceuticals and the management of its U.
S.
subsidiaries.
work
.
According to information released by Gan & Lee Pharmaceuticals, Dr.
Mike Hu has a doctorate in pharmacy from Shenyang Pharmaceutical University and completed postdoctoral research at Yale University School of Medicine.
Over 20 years of industry experience in research, clinical development and approval
.
Before joining Gan & Lee, Dr.
Mike Hu served as Chief Development Officer at Rafael Pharmaceuticals in the United States
.
Before that, Dr.
Mike Hu also worked in Novartis, GlaxoSmithKline, Jazz Pharmaceuticals and other companies, and held a number of preclinical research and clinical development leadership positions
.
Huahai Pharmaceutical Vice President Wang Jie resigns On January 3, Huahai Pharmaceutical announced that the board of directors recently received the resignation document of the company's vice president Wang Jie.
Since the receipt of the resignation document, Wang Jie will no longer hold any positions in the company
.
The announcement shows that his departure will not affect the normal operation of the company
.
Boaoxin Bio appointed Ye Xinliang as Chief Strategy Officer On January 3, Boaoxin Bio announced that Ye Xinliang will serve as the company's chief strategy officer and head of business development in China, responsible for Boaoxin's corporate strategic planning and business development in China.
expansion, financing,
etc.
According to public information, before joining Boaoxin, Mr.
Ye Xinliang served as the vice president of CStone Pharmaceuticals, responsible for the company's corporate strategy, capital market and investor relations.
.
In addition, earlier, Mr.
Ye Xinliang was the head of Abbott's business economics and strategic planning department in North Asia; before joining Abbott, he was also the project manager of LEK Consulting, focusing on the strategy of the life science industry Formulations and mergers and acquisitions
.
Qinhao Pharma Appoints Jie Jack Li (Li Jie) as Chief Scientific Officer On January 4, Qinhao Pharma announced the official appointment of Dr.
Jie Jack Li (Li Jie) as the company's Chief Scientific Officer, taking overall responsibility for the company's global early stage research and development of new drugs
.
According to reports, Dr.
Li Jie has more than 25 years of rich experience in medicinal chemistry and new drug research and development.
He has worked as a medicinal chemist in many large American pharmaceutical companies and biotechnology companies such as Pfizer, BMS and Revolution Medicine.
Important contributions to multiple therapeutic areas
.
Conclusion The industry expects that with the further deepening of the reform of the domestic pharmaceutical industry, many pharmaceutical companies will continue to change their executives in 2022 in order to speed up their transformation and upgrading and adjust their development strategies
.
.
In China, more than 100 senior executives left last year alone, involving a large number of domestic and foreign pharmaceutical companies such as Pfizer, AstraZeneca, Ascentage, WuXi Biologics, Sinopharm, Hengrui, and Lexin
.
It is worth noting that the time has now entered 2022, and in just a few days at the beginning of the new year, there have been new changes in the executives of many pharmaceutical companies
.
Gan & Lee Pharmaceuticals Appoints Dr.
Mike Hu as CEO and General Manager of Gan & Lee AmericaOn January 3, Gan & Lee Pharmaceuticals announced that it has appointed Dr.
Mike Hu as Gan & Lee America's CEO and General Manager to lead and be responsible for the global clinical development of Gan & Lee Pharmaceuticals and the management of its U.
S.
subsidiaries.
work
.
According to information released by Gan & Lee Pharmaceuticals, Dr.
Mike Hu has a doctorate in pharmacy from Shenyang Pharmaceutical University and completed postdoctoral research at Yale University School of Medicine.
Over 20 years of industry experience in research, clinical development and approval
.
Before joining Gan & Lee, Dr.
Mike Hu served as Chief Development Officer at Rafael Pharmaceuticals in the United States
.
Before that, Dr.
Mike Hu also worked in Novartis, GlaxoSmithKline, Jazz Pharmaceuticals and other companies, and held a number of preclinical research and clinical development leadership positions
.
Huahai Pharmaceutical Vice President Wang Jie resigns On January 3, Huahai Pharmaceutical announced that the board of directors recently received the resignation document of the company's vice president Wang Jie.
Since the receipt of the resignation document, Wang Jie will no longer hold any positions in the company
.
The announcement shows that his departure will not affect the normal operation of the company
.
Boaoxin Bio appointed Ye Xinliang as Chief Strategy Officer On January 3, Boaoxin Bio announced that Ye Xinliang will serve as the company's chief strategy officer and head of business development in China, responsible for Boaoxin's corporate strategic planning and business development in China.
expansion, financing,
etc.
According to public information, before joining Boaoxin, Mr.
Ye Xinliang served as the vice president of CStone Pharmaceuticals, responsible for the company's corporate strategy, capital market and investor relations.
.
In addition, earlier, Mr.
Ye Xinliang was the head of Abbott's business economics and strategic planning department in North Asia; before joining Abbott, he was also the project manager of LEK Consulting, focusing on the strategy of the life science industry Formulations and mergers and acquisitions
.
Qinhao Pharma Appoints Jie Jack Li (Li Jie) as Chief Scientific Officer On January 4, Qinhao Pharma announced the official appointment of Dr.
Jie Jack Li (Li Jie) as the company's Chief Scientific Officer, taking overall responsibility for the company's global early stage research and development of new drugs
.
According to reports, Dr.
Li Jie has more than 25 years of rich experience in medicinal chemistry and new drug research and development.
He has worked as a medicinal chemist in many large American pharmaceutical companies and biotechnology companies such as Pfizer, BMS and Revolution Medicine.
Important contributions to multiple therapeutic areas
.
Conclusion The industry expects that with the further deepening of the reform of the domestic pharmaceutical industry, many pharmaceutical companies will continue to change their executives in 2022 in order to speed up their transformation and upgrading and adjust their development strategies
.
